Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TVB-3567
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sagimet IND Cleared for TVB-3567, a FASN Inhibitor for Acne Treatment
Details : TVB-3567 is a potent and selective small molecule FASN inhibitor is planned to enter clinical development for the treatment of acne.
Product Name : TVB-3567
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2025
Lead Product(s) : TVB-3567
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sagimet Completes FDA Phase 2 for Denifanstat, Phase 3 for MASH By End 2024
Details : Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of MASH.
Product Name : TVB-2640
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2024
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sagimet Completes Phase 1 Hepatic Impairment Study of FASN Inhibitor Denifanstat
Details : TVB-264 (denifanstat) is a selective FASN inhibitor, which is under clinical development for the treatment of metabolic dysfunction-associated steatohepatitis/Non-alcoholic Steatohepatitis.
Product Name : TVB-2640
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2024
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sagimet Announces Positive Results from Phase 2b of Denifanstat in F2/F3 NASH
Details : TVB-2640 (denifanstat) is an orally bioavailable fatty acid synthase (FASN) inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of Nonalcoholic Fatty Liver Disease.
Product Name : TVB-2640
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2024
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gannex's Partner Sagimet Announces Positive Results From Phase 2b Trial Of Denifanstat
Details : TVB-2640 (denifanstat) is an oral, selective FASN inhibitor which is under phase 2 clinical development for the treatment of non-alcoholic steatohepatitis patients with stage 2 or stage 3 fibrosis.
Product Name : TVB-2640
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2024
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
Details : TVB-264 (denifanstat) is a selective FASN inhibitor, which is under clinical development for the treatment of metabolic dysfunction-associated steatohepatitis/Non-alcoholic Steatohepatitis.
Product Name : TVB-2640
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2024
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Denifanstat,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Ascletis Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated in combined with bevacizumab for the treatment of recurrent glioblastoma.
Product Name : TVB-2640
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 27, 2023
Lead Product(s) : Denifanstat,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Ascletis Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : An analysis of the full patient population at 52 weeks will evaluate the impact of TVB-2640 (denifanstat) treatment or placebo as assessed by biopsy, with primary efficacy endpoints that include improvement in NASH activity score or improvement in fibros...
Product Name : TVB-2640
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2022
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Denifanstat (formerly known as TVB-2640) is a wholly owned, oral, selective inhibitor of FASN, a key enzyme involved in the production of saturated fatty acids in the liver and other organs.
Product Name : TVB-2640
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Denifanstat (TVB-2640), the company’s lead product candidate, is an oral, selective, first-in-class fatty acid synthase inhibitor. Denifanstat’s unique mechanism of action directly targets the primary drivers of NASH by reducing excess liver fat.
Product Name : TVB-2640
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2022
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable